基因名称：EPHB2 （EPH receptor B2）
别名： CAPB,DRT,EK5,EPHT3,ERK,Hek5,PCBC,Tyro5
基因ID：2048
Chromosome(GRCh37) ：1 Start: 23037332 End: 23241818 Strand: 1
信号通路：
靶向药：
化疗药：
简介：该基因编码受体酪氨酸激酶跨膜糖蛋白的EPH受体家族的一个成员。这些受体由N端糖基化配体结合域、跨膜区和细胞内激酶域组成。结合称为肾素的配体，并参与多种细胞过程，包括运动、分裂和分化。EPH-肾素信号的一个区别特征是受体和配体都有能力传导信号级联，从而产生双向信号。这种蛋白属于一个称为EPHB的EPH受体亚群。通过序列同源性和对膜结合的肾素B配体的优先结合亲和力，将这一亚群的蛋白质与家族其他成员区别开来。等位基因变异与前列腺癌和脑癌易感性相关。选择性剪接导致多个转录变体。This gene encodes a member of the Eph receptor family of receptor tyrosine kinase transmembrane glycoproteins. These receptors are composed of an N-terminal glycosylated ligand-binding domain, a transmembrane region and an intracellular kinase domain. They bind ligands called ephrins and are involved in diverse cellular processes including motility, division, and differentiation. A distinguishing characteristic of Eph-ephrin signaling is that both receptors and ligands are competent to transduce a signaling cascade, resulting in bidirectional signaling. This protein belongs to a subgroup of the Eph receptors called EphB. Proteins of this subgroup are distinguished from other members of the family by sequence homology and preferential binding affinity for membrane-bound ephrin-B ligands. Allelic variants are associated with prostate and brain cancer susceptibility. Alternative splicing results in multiple transcript variants.
EPHB2突变与药物：
EPHB2
药物：
Ziv-阿柏西普
疾病：
前列腺癌
Single nucleotide variant NM_004442.7(EPHB2):c.2035G>003eA (p.Asp679Asn)
药物：
Ziv-阿柏西普
疾病：
前列腺癌
